MX2018009913A - Aglutinantes max como moduladores myc y sus usos. - Google Patents
Aglutinantes max como moduladores myc y sus usos.Info
- Publication number
- MX2018009913A MX2018009913A MX2018009913A MX2018009913A MX2018009913A MX 2018009913 A MX2018009913 A MX 2018009913A MX 2018009913 A MX2018009913 A MX 2018009913A MX 2018009913 A MX2018009913 A MX 2018009913A MX 2018009913 A MX2018009913 A MX 2018009913A
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- myc
- binders
- max
- modulators
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 101150094258 mxi1 gene Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662295996P | 2016-02-16 | 2016-02-16 | |
| PCT/US2017/018162 WO2017143059A1 (en) | 2016-02-16 | 2017-02-16 | Max binders as myc modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018009913A true MX2018009913A (es) | 2018-11-29 |
Family
ID=58191662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009913A MX2018009913A (es) | 2016-02-16 | 2017-02-16 | Aglutinantes max como moduladores myc y sus usos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10106555B2 (enExample) |
| EP (1) | EP3416950A1 (enExample) |
| JP (1) | JP2019505548A (enExample) |
| KR (1) | KR20180107261A (enExample) |
| CN (1) | CN109071456A (enExample) |
| AU (1) | AU2017221422A1 (enExample) |
| BR (1) | BR112018016133A2 (enExample) |
| CA (1) | CA3012846A1 (enExample) |
| MX (1) | MX2018009913A (enExample) |
| RU (1) | RU2018132559A (enExample) |
| WO (1) | WO2017143059A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2018132559A (ru) | 2016-02-16 | 2020-03-17 | Массачусетс Инститьют Оф Текнолоджи | Связывающие молекулы для max в качестве модуляторов myc и их применения |
| US11613535B2 (en) * | 2018-07-09 | 2023-03-28 | The Scripps Research Institute | Compounds for MYC inhibition |
| EP4058454A4 (en) * | 2019-11-08 | 2023-12-13 | Sanford Burnham Prebys Medical Discovery Institute | APOPTOSIS INHIBITORS (IAP) PROTEIN ANTAGONISTS |
| CN111274691A (zh) * | 2020-01-16 | 2020-06-12 | 西安交通大学 | 一种分析预测max相材料可形成能力的方法 |
| WO2021195360A1 (en) | 2020-03-27 | 2021-09-30 | Landos Biopharma, Inc. | Plxdc2 ligands |
| AU2022207648A1 (en) | 2021-01-13 | 2023-07-27 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| CN116908444B (zh) * | 2023-09-13 | 2023-12-19 | 中国医学科学院北京协和医院 | 血浆max自身抗体在晚期非小细胞肺癌pd-1单抗联合化疗治疗预后预测中的应用 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02191695A (ja) | 1989-01-20 | 1990-07-27 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02194085A (ja) | 1989-01-24 | 1990-07-31 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02196887A (ja) | 1989-01-26 | 1990-08-03 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02208392A (ja) | 1989-02-08 | 1990-08-17 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02222488A (ja) | 1989-02-23 | 1990-09-05 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02227489A (ja) | 1989-02-28 | 1990-09-10 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02227490A (ja) | 1989-02-28 | 1990-09-10 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02227491A (ja) | 1989-03-01 | 1990-09-10 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02242882A (ja) | 1989-03-16 | 1990-09-27 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02247280A (ja) | 1989-03-20 | 1990-10-03 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02247282A (ja) | 1989-03-22 | 1990-10-03 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02255794A (ja) | 1989-03-29 | 1990-10-16 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02255793A (ja) | 1989-03-30 | 1990-10-16 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| US5965574A (en) | 1996-08-13 | 1999-10-12 | Chen; Yuhpyng Liang | Heteroaryl amines as novel acetylcholinesterase inhibitors |
| JPH08231541A (ja) | 1995-03-01 | 1996-09-10 | Nippon Soda Co Ltd | イミダゾリン誘導体および除草剤 |
| AU6331099A (en) | 1998-09-30 | 2000-04-17 | Roche Diagnostics Gmbh | Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders |
| WO2000023451A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
| CA2431083C (en) | 2000-12-18 | 2011-08-09 | Institute Of Medicinal Molecular Design, Inc. | Inflammatory cytokine release inhibitor |
| US6452014B1 (en) | 2000-12-22 | 2002-09-17 | Geron Corporation | Telomerase inhibitors and methods of their use |
| JP2003057783A (ja) | 2001-08-21 | 2003-02-26 | Konica Corp | 銀色調を改良した光熱写真画像形成材料 |
| JP2003075955A (ja) | 2001-09-03 | 2003-03-12 | Konica Corp | 銀色調を改良した光熱写真画像形成材料 |
| JP2003075957A (ja) | 2001-09-07 | 2003-03-12 | Konica Corp | スケイル模様のない光熱写真画像形成材料 |
| US7879893B2 (en) | 2001-09-14 | 2011-02-01 | Novo Nordisk A/S | Ligands for the HisB10 Zn2 + sites of the R-state insulin hexamer |
| US20050042674A9 (en) | 2002-02-21 | 2005-02-24 | Lin Yu | Common ligand mimics: thiazolidinediones and rhodanines |
| GB2387172A (en) | 2002-03-28 | 2003-10-08 | Pantherix Ltd | [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials |
| JP2006500399A (ja) | 2002-04-30 | 2006-01-05 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャンネルブロッカーとしての、アリール−結合−アリール置換された、チアゾリジン−ジオンおよびオキサゾリジン−ジオン |
| JP4211433B2 (ja) | 2002-08-14 | 2009-01-21 | 三菱化学株式会社 | 有機金属錯体、発光色素、有機電界発光素子材料および有機電界発光素子 |
| WO2004080989A1 (ja) | 2003-03-10 | 2004-09-23 | Sumitomo Chemical Company Limited | フラン化合物の製造方法 |
| US7777051B2 (en) | 2003-05-13 | 2010-08-17 | Icagen, Inc. | Asymmetric benzimidazoles and related compounds as potassium channel modulators |
| US20060074124A1 (en) | 2003-09-12 | 2006-04-06 | Andrew Napper | Methods of treating a disorder |
| EP1677794B1 (en) | 2003-09-12 | 2014-12-03 | Elixir Pharmaceuticals, Inc. | Methods of treating disorder |
| WO2005033090A1 (ja) | 2003-10-06 | 2005-04-14 | Sumitomo Chemical Company, Limited | 芳香族化合物 |
| EP1768694A1 (en) | 2004-07-09 | 2007-04-04 | Novo Nordisk A/S | Phamaceutical preparations comprising insulin |
| JP2006084592A (ja) | 2004-09-14 | 2006-03-30 | Fuji Photo Film Co Ltd | 感光性組成物 |
| EP1746097B1 (en) | 2005-07-20 | 2010-01-13 | Aventis Pharma S.A. | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them |
| WO2007047604A2 (en) | 2005-10-18 | 2007-04-26 | Elixir Pharmaceuticals, Inc. | Sirt1 inhibition |
| JP4931434B2 (ja) | 2006-02-14 | 2012-05-16 | 株式会社ダイセル | アミノ基含有アダマンタン誘導体とその製造方法 |
| AU2007257959A1 (en) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
| EP2049548A1 (en) | 2006-07-27 | 2009-04-22 | UCB Pharma, S.A. | Fused oxazoles & thiazoles as histamine h3- receptor ligands |
| EP2219646A4 (en) | 2007-12-21 | 2010-12-22 | Univ Rochester | PROCESS FOR EXTENDING THE LIFE OF EUKARYOTIC ORGANISMS |
| AU2009207693A1 (en) | 2008-01-24 | 2009-07-30 | Ucb Pharma, S.A. | Compounds comprising a cyclobutoxy group |
| JP2011517317A (ja) | 2008-02-28 | 2011-06-02 | ライフ テクノロジーズ コーポレーション | 蛍光偏光ｈＥＲＧアッセイ法 |
| AU2009313198B2 (en) | 2008-11-10 | 2016-03-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8865909B2 (en) | 2008-11-20 | 2014-10-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-biofilm agents |
| US20120040916A1 (en) | 2008-12-22 | 2012-02-16 | Massachusetts Institute Of Technology | Molecular inhibitors of the wnt/beta-catenin pathway |
| JP5046213B2 (ja) | 2009-03-12 | 2012-10-10 | 独立行政法人科学技術振興機構 | 光学活性アルコール化合物の製法 |
| EP2504344A4 (en) | 2009-11-24 | 2013-06-05 | Boehringer Ingelheim Int | HEPATITIS C INHIBITOR COMPOUNDS |
| ES2629170T3 (es) | 2009-12-04 | 2017-08-07 | Senhwa Biosciences, Inc. | Pirazolopirimidinas y heterociclos relacionados como inhibidores de CK2 |
| EP2617722B1 (en) | 2010-09-10 | 2016-03-23 | Shionogi & Co., Ltd. | Hetero ring-fused imidazole derivative having ampk activating effect |
| US9537111B2 (en) | 2011-05-11 | 2017-01-03 | Idemitsu Kosan Co., Ltd. | Compound, material for organic electroluminescence device, and organic electroluminescence device |
| CN103649067A (zh) | 2011-09-13 | 2014-03-19 | 出光兴产株式会社 | 稠合杂芳香族衍生物、有机电致发光元件用材料及使用其的有机电致发光元件 |
| JP6653573B2 (ja) | 2012-05-22 | 2020-02-26 | トラスティーズ・オブ・ダートマウス・カレッジ | シクロアルカニル［ｂ］インドール、シクロアルカニル［ｂ］ベンゾフラン、シクロアルカニル［ｂ］ベンゾチオフェンを合成するための方法、化合物および使用の方法 |
| PL3486245T3 (pl) * | 2012-12-07 | 2021-11-08 | Vertex Pharmaceuticals Incorporated | 2-amino-n-(piperydyn-1-ylo-pirydyn-3-ylo) pirazolo[1,5alfa]pirymidyno-3-karboksyamid jako inhibitor kinazy atr |
| CN105246876B (zh) | 2013-02-28 | 2017-06-16 | 住友化学株式会社 | 稠合杂环化合物及其有害生物防除用途 |
| US8901164B2 (en) * | 2013-03-07 | 2014-12-02 | University Of Maryland, Baltimore | Amphipathic and other double-sided alpha-helix mimetics based on a 1,2-diphenylacetylene scaffold |
| KR20150135359A (ko) | 2013-03-14 | 2015-12-02 | 컨버진 엘엘씨 | 브로모도메인-함유 단백질의 억제를 위한 방법 및 조성물 |
| US9242944B2 (en) * | 2013-03-27 | 2016-01-26 | University Of Maryland, Baltimore | Potent analogues of the C-Myc inhibitor 10074-G5 with improved cell permeability |
| CA2942574A1 (en) * | 2013-12-11 | 2015-06-18 | The Scripps Research Institute | Small molecule c-myc inhibitors |
| WO2016094688A1 (en) | 2014-12-10 | 2016-06-16 | Massachusetts Institute Of Technology | Fused 1,3-azole derivatives useful for the treatment of proliferative diseases |
| RU2018132559A (ru) | 2016-02-16 | 2020-03-17 | Массачусетс Инститьют Оф Текнолоджи | Связывающие молекулы для max в качестве модуляторов myc и их применения |
-
2017
- 2017-02-16 RU RU2018132559A patent/RU2018132559A/ru not_active Application Discontinuation
- 2017-02-16 MX MX2018009913A patent/MX2018009913A/es unknown
- 2017-02-16 US US15/435,003 patent/US10106555B2/en active Active
- 2017-02-16 KR KR1020187026354A patent/KR20180107261A/ko not_active Withdrawn
- 2017-02-16 BR BR112018016133A patent/BR112018016133A2/pt not_active Application Discontinuation
- 2017-02-16 EP EP17708095.9A patent/EP3416950A1/en not_active Withdrawn
- 2017-02-16 AU AU2017221422A patent/AU2017221422A1/en not_active Abandoned
- 2017-02-16 CA CA3012846A patent/CA3012846A1/en not_active Abandoned
- 2017-02-16 CN CN201780011783.5A patent/CN109071456A/zh active Pending
- 2017-02-16 WO PCT/US2017/018162 patent/WO2017143059A1/en not_active Ceased
- 2017-02-16 JP JP2018543356A patent/JP2019505548A/ja active Pending
-
2018
- 2018-10-22 US US16/167,238 patent/US10865213B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109071456A (zh) | 2018-12-21 |
| RU2018132559A (ru) | 2020-03-17 |
| EP3416950A1 (en) | 2018-12-26 |
| KR20180107261A (ko) | 2018-10-01 |
| JP2019505548A (ja) | 2019-02-28 |
| BR112018016133A2 (pt) | 2019-01-02 |
| US20190144466A1 (en) | 2019-05-16 |
| US10865213B2 (en) | 2020-12-15 |
| US20170233405A1 (en) | 2017-08-17 |
| WO2017143059A1 (en) | 2017-08-24 |
| US10106555B2 (en) | 2018-10-23 |
| AU2017221422A1 (en) | 2018-08-16 |
| CA3012846A1 (en) | 2017-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018009913A (es) | Aglutinantes max como moduladores myc y sus usos. | |
| AU2018236742B2 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
| MX2018009633A (es) | Inhibidor de indoleamina-2,3-dioxigenasa (ido). | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| MX2018009496A (es) | Degradadores selectivos del receptor de estrogeno y sus usos. | |
| PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
| JOP20190151A1 (ar) | مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| NZ754051A (en) | Novel antibodies and uses thereof | |
| EP4566675A3 (en) | Heterocyclic compounds as immunomodulators | |
| WO2018226622A8 (en) | Compounds for treating huntington's disease | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| PH12018501226A1 (en) | Methods for treating huntingtons disease | |
| WO2017176957A8 (en) | Mdm2 protein degraders | |
| EP4026835A3 (en) | Pd-1/pd-l1 inhibitors | |
| MA40074A (fr) | Composés liant ras multivalents | |
| EP4353235A3 (en) | Nlrp3 modulators | |
| EP4285906A3 (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof | |
| MX2022008523A (es) | Compuestos que interactuan con glicanos y metodos de uso. | |
| MX395142B (es) | Marcadores selectivamente desregulados en celulas t reguladoras, infiltrantes de tumores. | |
| MX2020012679A (es) | Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos. | |
| EA200870415A1 (ru) | Хиназолины для ингибирования pdk 1 | |
| CR11207A (es) | Compuestos organicos | |
| ZA202100485B (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
| WO2015108998A8 (en) | Cartilage targeting agents and their use |